Abcellera Biologics Inc
ABCL4.170USD
-0.050-1.18%
종가 09/08, 16:00（ET）시세는 15분 지연됩니다
1.25B시가총액
손실P/E TTM
자세한 내용은 Abcellera Biologics Inc 회사
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
회사 정보
종목 코드 ABCL
회사 이름Abcellera Biologics Inc
상장일Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
직원 수596
유형Ordinary Share
회계 연도 종료Dec 11
주소150 W 4Th Avenue
도시VANCOUVER
증권 거래소NASDAQ Global Select Consolidated
국가Canada
우편 번호V5Y 1G6
전화16045599005
웹사이트https://www.abcellera.com/
종목 코드 ABCL
상장일Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
수익 분석
통화: USD마지막 업데이트: Sat, Feb 22
통화: USD마지막 업데이트: Sat, Feb 22
FY2024Q2
FY2023Q2
사업별USD
이름
수익
비율
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
데이터 없음
사업별
지역별
사업별USD
이름
수익
비율
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
주식 보유 통계
마지막 업데이트: Sat, Aug 16
마지막 업데이트: Sat, Aug 16
주주
주주 유형
주주
주주
비율
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
기타
60.85%
주주
주주
비율
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
기타
60.85%
주주 유형
주주
비율
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.65%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.99%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.63%
Venture Capital
0.32%
기타
38.92%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
2023Q1
423
223.82M
78.22%
-38.92M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Thermopylae Holdings Ltd
56.14M
18.81%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.22%
--
--
Mar 31, 2025
Capital World Investors
13.36M
4.48%
+5.43M
+68.41%
Mar 31, 2025
Baillie Gifford & Co.
11.20M
3.75%
-1.04M
-8.50%
Mar 31, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
5.77M
1.93%
-94.12K
-1.60%
Mar 31, 2025
UBS Asset Management (Americas) LLC
6.61M
2.21%
+6.61M
--
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.38%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
9.06M
3.04%
+4.56M
+101.35%
Mar 31, 2025
UBS Switzerland AG
5.05M
1.69%
+4.91M
+3556.81%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
iShares Genomics Immunology and Healthcare ETF
1.77%
TrueShares Technology, AI & Deep Learning ETF
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
SPDR S&P International Small Cap ETF
0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율1.77%
TrueShares Technology, AI & Deep Learning ETF
비율1.53%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.98%
Invesco Nasdaq Biotechnology ETF
비율0.13%
ProShares Ultra Nasdaq Biotechnology
비율0.11%
iShares Biotechnology ETF
비율0.1%
SPDR S&P International Small Cap ETF
비율0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
비율0.02%
Avantis US Small Cap Equity ETF
비율0.01%
SPDR Portfolio Developed World ex-US ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
